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Despite of multiple solid steps taken to control drug 
resistance it is still emerging a dilemma of the civilized 
world. The emergence of drug resistance is credited to 
over and inappropriately use of antimicrobial drugs. 
I n t r o d u c t i o n 
Objective: To establish (i) if carbapenemases are a major cause of carbapenem resistance in Enterobacteriaceae and 
belong to metallo- β-lactamases (ii) Which one is the best phenotypic method for the detection of metallo- β-lactamases. 
Patients and Methods: This cross-sectional study was conducted at pathology department, Punjab Institute of 
Cardiology Lahore. Samples were randomly enrolled from daily lab work and analysed. During the period of September 2016 
to January 2017, a total of 2970 clinical samples were enrolled and processed for bacterial culture. Every isolate of 
Enterobacteriaceae was processed for detection of carbapenem resistance and for the detection of carbapenemases 
producers by modified Hodge test. Metallo- β-lactamases detection (MBL) was done by three different phenotypic 
techniques, (i) Combined disk technique (0.1 M EDTA), (ii) (0.5 M EDTA). (iii) Double disk synergy technique (DSST). 
Results: Out of total n=2970 samples, 38.7% (n=1150) were culture positive of which 40.5% (n=550) were 
Enterobacteriaceae. Among these, 9.0 % (n=50) were carbapenem-resistant; 98% (49/50) were carbapenemase 
producers (modified Hodge test -Positive). According to (i) Combined disk technique (0.1 M EDTA), 98% (48/49) were 
metallo- β-lactamases positive (ii) Combined disk technique (0.5 M EDTA), 86% (42/49) were metallo- β-lactamases, 2% 
(1/49) were non-determinable (iii) Double disk synergy technique (DDST) showed 100% (49/49) isolates were metallo- β-
lactamases positive. Chloramphenicol and Tigecycline were found sensitive in 28% and 16% respectively; all other 
antimicrobials were highly resistant against carbapenem-resistant isolates. 
Conclusion: Carbapenemases are a major cause of carbapenem resistance in Enterobacteriaceae. Double-disk 
synergy technique is good for the detection of MBL as compared to other phenotypic methods. Each carbapenem- 
resistant isolate of Enterobacteriaceae should be process for the detection of Carbapenemase especially MBL. 
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Carbapenems are the most commonly used drugs against 
multi-drug resistant (MDR) and extended spectrum beta-
lactamases (ESBL) strains of Enterobacteriaceae.1, 2 The 
emergence and spread of resistance in 
Enterobacteriaceae are complicating the treatment of 
serious nosocomial infections and threatening to create 
species resistant to all currently available agents. The 
vast majority of Enterobacteriaceae, including ESBL 
producers, remain susceptible to Carbapenems, and 
these agents are considered preferred empirical therapy 
for serious Enterobacteriaceae infections. Carbapenem 
resistance, although rare, appears to be increasing.3 
Carbapenemases (Metallo ß-lactamases or MBLs) have 
been emerged and spread from P. aeruginosa to 
Enterobacteriaceae.4 Better antibiotic stewardship and 
strict infection control programs are needed to prevent 
further spread of ESBLs and other forms of resistance in 
Enterobacteriaceae throughout the world.3 
Resistance to Carbapenems develops when bacteria 
acquire or develop structural changes within their 
Penicillin Binding Proteins (PBP), when they acquire MBL 
that are capable of rapidly degrading Carbapenems, or 
when changes in membrane permeability arise as a result 
of the loss of specific outer membrane porins.5 Several 
resistance mechanisms occur to evade the efficacy of 
Carbapenem and the Carbapenemases are the most 
prominent enzymes that neutralize Carbapenem.6 
First, high-level production of chromosomal AmpC 
cephalosporins combined with decreased outer 
membrane permeability due to loss or alteration of porins 
can result in carbapenem resistance. This has been 
shown for Enterobacter cloacae, Enterobacter aerogenes, 
Proteus rettgeri, Citrobacter freundii, Escherichia coli and 
K. pneumonia. The second mechanism is the production 
of a β-lactamase, that is capable of hydrolysing 
carbapenems (e.g., IMI-1, IMP-1, Nmc-A, Sme-1, and 
CFIA). The third mechanism of resistance involves 
changes in the affinity of the target enzymes, the 
penicillin-binding proteins, for Carbapenems.7 The rapid 
global spread of K. pneumoniae that produces K. 
pneumoniae carbapenemase (KPC) is of major concern. 
The most common mechanism of resistance for the β-
lactam antibiotic in clinically important gram-negative 
bacteria is hydrolysis of this group by β-lactamases.8 
Carbapenemases are β-lactamases with versatile 
hydrolytic capacities. They have the ability to hydrolyse 
penicillins, cephalosporins, monobactams, and 
carbapenems. Bacteria producing these β-lactamases 
may cause serious infections in which the 
carbapenemase activity renders many β-lactams 
ineffective. Carbapenemases are members of the 
molecular class A, B, and D β-lactamases. Class A and D 
enzymes have a serine-based hydrolytic mechanism, 
while class B enzymes are metallo-β-lactamases that 
contain zinc in the active site. 9 Rapid detections of 
carbapenemases especially MBL producing gram-
negative pathogens is crucial to prevent their widespread 
dissemination.10 KPC genes are typically located on 
mobile genetic elements, especially a particular 
transposon known as Tn4401, which helps transfer 
between plasmids and across bacterial species. Tn4401 
and related transposons have been detected in many 
species from different continents.11 Several methods 
including modified Hodge test, double disc synergy 
method using imipenem-EDTA discs, EDTA- impregnated 
imipenem disc and EDTA impregnated meropenem discs 
and imipenem- EDTA impregnated E- test strips have 
also been recommended.12, 13 
As carbapenemase mediated carbapenem resistance is 
more of a challenge for infection control than other forms 
of carbapenem resistance in Enterobacteriaceae, so this 
study will help in establishing a method for early detection 
of carbapenemase and this, in turn will lead to prompt 
measures to check their dissemination and will have a 
valuable importance in infection control. 
P a t i e n t s  a n d  M e t h o d s  
This cross-sectional analytical type of study was carried in 
the pathology department of Punjab Institute of 
Cardiology Lahore. Samples were randomly enrolled from 
daily lab work during the period of January 2016 to 
January 2017 and analysed. A total of 2970 clinical 
samples were enrolled, every sample was processed for 
bacterial culture. Bacterial identification was done by 
colonial morphology, Gram stain and standard 
biochemical profile API-20 E. Every Enterobacteriaceae 
isolate was processed for antimicrobial susceptibility 
testing for the detection of carbapenem-resistant, and all 
those isolates that were carbapenem-resistant were 
further analyzed for the detection of carbapenemases 
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producers by modified Hodge test (MHT). Moreover, 
every carbapenemase producer (MHT-positive) isolate 
was tested for the detection of MBL produced by three 
different phenotypic methods. Only carbapenem-resistant 
isolates of Enterobacteriaceae were included. Repeat 
isolates of Enterobacteriaceae from all the specimens of 
the same patients were excluded. 
Modified Hodge Test: A 0.5 McFarland (1:10) dilution of 
E. coli ATCC 25922 was prepared and inoculated on 
mueller Hinton agar, A 10-µgram meropenem disk was 
placed in the centre and in a straight line, test organism 
was streaked from the edge of the disk to the edge of the 
plate and was incubated at 35+2 in ambient air for 16-24 
hours. After incubation, the plates were examined for a 
cloverleaf-type indentation at the intersection of the test 
organism and the E. coli 25922, within the zone of 
inhibition of the carbapenem susceptibility disk. MHT 
Positive test had a clover leaf-like indentation of the E.coli 
25922 growing along the test organism growth streak 
within the disk diffusion zone. While MHT Negative test 
had no growth of the E.coli 25922 along the test organism 
growth streak within the disc diffusion. For quality control 
purpose Klebsiella pneumonia ATCC® BAA-1705 were 
used as positive control and Klebsiella pneumonia 
ATCC® BAA-1706 were used as negative control. 
MBL Detection: MBL detection was done by phenotypic 
techniques, using single agar plate (Mueller-Hinton agar) 
inoculated with test organism and comprised of three 
components. 
Combined Disk Technique (0.1 M EDTA): Two 
Imipenem disks (10 µg), one containing 10µl of 0.1M 
(292µg) anhydrous EDTA, were placed 25 mm apart. 10 
µl of 0.1 M (292 µg) EDTA was chosen, as higher 
concentration led to inhibitory effects with the EDTA 
alone. An increase in zone diameter of > 4mm around the 
IPM-EDTA disk compared to that of the IPM disk alone 
was considered positive for an MBL. 
Combined Disk Technique (0.5 M EDTA): A 0.5 M 
EDTA solution was prepared (pH= 8.0). Two disks of 10 
µg imipenem were placed on mueller-Hinton agar and to 
one of them, 4 µL of EDTA solution was added.  One 
blank disk with EDTA was also added as an EDTA 
control. Inhibition zones of imipenem alone and imipenem 
plus EDTA disks were read after 18-24 hours’ incubation 
at 350C. For MBL-positive organisms, addition of EDTA to 
the imipenem disk (imipenem plus EDTA) increased the 
inhibition zone by 8-15 mm (mean 10.5 mm), while the 
increase for MBL-negative isolates was 1-5 mm (mean) 
3.8 mm 
Double Disk Synergy Technique: In DDST, an 
imipenem (10µg) disk was placed 20mm apart (center to 
center) from a blank disk containing 10µl of 0.1 M EDTA. 
Enhancement of zone of inhibition in the area between 
two disks was considered positive for an MBL. Statistical 
Package for Social Sciences (SPSS) version 21.0 was 
used for statistical analysis of the data, Descriptive 
statistics were applied.  
R e s u l t s  
Out of total 2970 samples, 38.7% (n=1150) were culture 
positive of which 40.5% (n=550) were 
Enterobacteriaceae. Figure: 1. 
 
Figure 1: Breakup of culture positive isolates 
(n=2970) 
Among this 9.0 % (n=50) were carbapenem-resistant 
isolates of which 98% (49/50) were found to be positive 
for carbapenemase production (MHT-Positive) Figure: 2.  
 
Figure 2: Frequency of Carbapenamases producers 
(n=50) 
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Figure 3: Breakup of three different modalities for the 
detection of MBL producers’ (n=49) 
Table:1 Antimicrobial resistant pattern of 
carbapenem resistant isolates 
Antimicrobial drugs Frequency Percentage 
Chloramphenicol 36 72 
Tigecycline  42 84 
Amikacin  47 94 
Nalidixic Acid  49 98 
Ciprofloxacin  49 98 
Moxifloxacin  49 98 
Cefoperazone+sulbactam  49 98 
Co-Trimaxazole  49 98 
Meropenem  50 100 
Imipenem  50 100 
Cefotaxime  50 100 
Ceftazidime  50 100 
Augmentin  50 100 
Cefepime  50 100 
Tazobactam+Piperacillin,  50 100 
Tetracycline,  50 100 
Piperacillin+sulbactam,  50 100 
Ticarcillin+Clavulanic 
Acid  
50 100 
Gentamicin 50 100 
According to (i) Combined Disk Technique (0.1 M EDTA), 
98% (48/49) were MBL positive (ii) Combined disk 
technique (0.5 M EDTA), 86% (42/49) isolates were found 
to be positive for MBL production, and 2% (1/49) were 
placed in a non-determinable category. (iii) Double disk 
synergy technique (DDST)100% (49/49) isolates were 
found to MBL positive. Figure:3 
Antimicrobial resistant pattern of carbapenem-resistant 
isolates is presented in Table:1 
D i s c u s s i o n  
The emergence of carbapenemases producers 
possesses alarming challenges as MDR infections around 
the globe. In the last 10 years, it has become a significant 
problem. These β-lactamases are able to hydrolyze the 
carbapenem and provide resistance to a broad spectrum 
of antibiotics. 9 Carbapenems are commonly used to treat 
infections caused by multidrug-resistant 
Enterobacteriaceae and they are one of the antibiotics of 
last resort for many bacterial infections, such as E. coli 
and K. Pneumonia ,14 but now the clinical use of this 
group is under threat with the emergence of acquired 
carbapenemase, particularly Ambler class B metallo-β-
lactamase (MBL) and worldwide spread of the resistance 
gene is becoming a potentially frightening scenario.15 The 
present study was planned to evaluate the major source 
of carbapenem resistance in clinical isolates of 
Enterobacteriaceae, whether it is due to enzyme 
production or any other mechanism. Detection of 
carbapenemase was carried out by modified Hodge 
method according to the guidelines recommended by 
CLSI-2016.16 The study further focuses on the detection 
of metallo-β-lactamase (MBL).Three different methods 
were used for detection of metallo-β-lactamase (MBL) 
which included double disc synergy method, combined 
disc method by using two different concentration of EDTA. 
This is the simplest, highly sensitive and specific method 
used in a number of widely published studies. Present 
study reported that of total n=2970 samples, 38.7% 
(n=1150) were culture positive, of which 40.5% (n=550) 
were Enterobacteriaceae. Among this 9.0 % (n=50) were 
carbapenem-resistant isolates of which 98% (49/50) were 
found to be positive for carbapenemase production (MHT-
Positive). According to (i) Combined disk technique (0.1 M 
EDTA), 98% (48/49) were MBL positive (ii) Combined disk 
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technique (0.5 M EDTA), 86% (42/49) isolates were found 
to be positive for MBL production, and 2% (1/49) were 
placed in a non-determinable category (iii) Double disk 
synergy technique (DDST)100% (49/49) isolates were 
found to MBL positive. We suspect that the pre-dominant 
MBL among these isolates is most probably new delhi 
metallo-β-lactamase (NDM-1) A similar study from India 17 
reported that 107 clinical isolates of gram negative rods 
(GNR) were processed for the detection of MBL, by using 
(EDTA) as MBL inhibitor. Four phenotypic techniques 
were used (i) Combined disk synergy test (CDST) with 
0.5M EDTA (ii) CDST with 0.1 M EDTA (iii) DDST with 
0.5M EDTA (iv) DDST with 0.1 M EDTA. Out of 107 only 
30 isolates were carbapenem resistant of which 21 (70%) 
isolates were MBL positive by CDST-0.1 M EDTA, 19 
(63.3%) by CDST-0.5M EDTA, 17 (56.6%) by DDST-0.1 
M EDTA, and 16 (53.3%) by DDST-0.5M EDTA. Every 
MBL-producer isolate was resistant to 
ampicillin/sulbactam while Polymyxin B was the only 
choice of drug with high sensitive rate. Therefore, CDST-
0.1 M EDTA was reported as the best technique for the 
detection of MBL producers. Furthermore sensitivity of 
CDST-0.1 M EDTA and DDST-0.1 M EDTA technique 
have reported 100% and 79% respectively.18 In our view, 
the best method to detect MBL production in 
Enterobacteriaceae is double disk synergy method 
because this method detected all the MBL producers. If 
we are using combined disk method, then we should 
perform it by both methods by using two different 
concentrations of EDTA until and unless one of these is 
recommended as gold standard after confirmation by 
molecular genetic analysis. Moreover, it is suggested that 
the method to be used as gold standard for detection of 
MBL should be confirmed by molecular genetic analysis 
of the MBL producers. In this study, we also tried to 
establish the sensitivity pattern of meropenem resistant 
Enterobacteriaceae to alternative antibiotics. Almost 20% 
isolates were found sensitive to chloramphenicol and 16% 
were susceptible to tigecycline. The sensitivity of all other 
antimicrobial tested in this study was poor against these 
organisms. Present study reflects that once an isolate is 
declared as carbapenemase producer, we will be left with 
a very limited choice of antibiotics because genes 
encoding these enzymes are clustered with those 
encoding to resistance to aminoglycosides and 
fluoroquinolones, thus further compromising our antibiotic 
choice for these isolates.3 Similarly Walsh et al 15 
mentioned very high resistant of MBL-producers against 
all Beta-lactams, aminoglycosides, tetracycline, and 
ﬂuoroquinolones group of antibiotics. Moreover, present 
study strongly supports the inevitable need to differentiate 
carbapenemases producers Enterobacteriaceae from 
other strains to limit their spread. Clinical microbiology 
laboratories should be able to distinguish MBL producer 
strains because the uncontrolled spread of these 
organisms will result in treatment failure eventually. 
Confirmation of these enzymes requires molecular 
analysis, by PCR or DNA sequencing. At present, there is 
not enough data available from our country about the 
prevalence of carbapenemases including MBL. Avoidance 
of unnecessary use of antimicrobials should be a part of 
the recommended drug therapy in hospitalized patients, 
especially in ICU. Regular surveillance programs should 
be conducted to check the drugs susceptibility, their 
usage pattern and resistance mechanism. Molecular 
genetic analysis of these enzymes by DNA probing and 
PCR is suggested for further studies. 
C o n c l u s i o n  
Double-disk synergy technique is good method for the 
detection of MBL producers as compared to other 
phenotypic methods. Making it highly applicable to routine 
clinical laboratories, each carbapenem-resistant isolate of 
Enterobacteriaceae should be processed for the detection 
of Carbapenemase especially MBL. 
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